文献速递骨质疏松与代谢性骨病

罗莫佐单抗对低骨量绝经前女性骨密度与骨小梁评分的影响

Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass.
PubMed 文献 · Osteoporos Int · 2025-01-15

该回顾性研究纳入25例接受罗莫佐单抗治疗的低骨量绝经前女性和5例未用药对照,治疗1年后罗莫佐单抗组腰椎骨密度增加12.8%、股骨颈骨密度增加4.6%、骨小梁评分增加4.1%,作者认为罗莫佐单抗可能是有潜力的治疗选择,但需进一步研究其对骨折风险的影响。

要点

  • 糖皮质激素诱导的骨质疏松和特发性骨质疏松亚组腰椎骨密度均显著增加,特发性骨质疏松亚组股骨颈骨密度显著增加。

核心结论

  • 罗莫佐单抗可增加低骨量绝经前女性的骨密度,可能是不论病因的低骨量绝经前女性的潜在治疗选择,但需进一步研究其对骨折风险的影响。

研究设计与样本

  • 回顾性研究,纳入接受罗莫佐单抗治疗的绝经前低骨量女性25例(罗莫佐单抗组)和未用药患者5例(对照组)。
  • 罗莫佐单抗组分为糖皮质激素诱导的骨质疏松12例、特发性骨质疏松9例、妊娠及哺乳期诱导的骨质疏松4例。
  • 治疗前及罗莫佐单抗治疗1年后测量骨密度和骨小梁评分。

主要发现

  • 罗莫佐单抗组平均年龄37.0岁(范围32.0-42.0),体重指数中位数18.8 kg/m2(范围17.5-21.3)。
  • 罗莫佐单抗组治疗后骨小梁评分较基线增加4.1%±3.8(p<0.001)。
  • 糖皮质激素诱导的骨质疏松和特发性骨质疏松亚组腰椎骨密度均显著增加,特发性骨质疏松亚组股骨颈骨密度显著增加。

临床怎么用

  • 原文结论认为罗莫佐单抗可能是不论病因的低骨量绝经前女性的潜在治疗选择,但需进一步研究其对骨折风险的影响。

局限性

  • 原文结论指出需进一步研究罗莫佐单抗对骨折风险的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We investigated the efficacy of romosozumab in premenopausal women with low bone mass. Romosozumab substantially increased bone mineral density and trabecular bone score in these women, aligning with its proven therapeutic benefits for postmenopausal osteoporosis. PURPOSE: Romosozumab, an anti-sclerostin antibody, is a promising anabolic agent that increases bone formation and decreases bone resorption. However, its efficacy in premenopausal women with low bone mass remains understudied. METHODS: We retrospectively reviewed premenopausal women with low bone mass treated with romosozumab (ROMO group) or drug-naïve patients (control group). Patients in the ROMO group were classified into the glucocorticoid-induced osteoporosis (GIOP), idiopathic osteoporosis (IOP), and pregnancy and lactation-induced osteoporosis (PLO) subgroups. Bone mineral density (BMD) and trabecular bone score (TBS) were measured before and after one year of romosozumab treatment. RESULTS: Twenty-five patients in the ROMO group and five in the control group were included in the study. Among patients in the ROMO group, 12 were in the GIOP, 9 in the IOP, and 4 in the PLO subgroups. The mean age was 37.0 years [32.0-42.0], and the median body mass index was 18.8 kg/m2 [17.5-21.3]. After romosozumab treatment, lumbar spine (LS), femur neck (FN) BMD, and TBS increased from baseline (LSBMD, 12.8% [8.2-19.3], p < 0.001; FNBMD, 4.6% [- 0.6-10.7], p = 0.016; TBS, 4.1% ± 3.8, p < 0.001) in the ROMO group. Patients in both the GIOP and IOP subgroups showed a significant increase in LSBMD, while those in the IOP subgroup demonstrated significant increases in FNBMD. CONCLUSION: We demonstrated romosozumab's efficacy in BMD increment in premenopausal women. Romosozumab may be a potential treatment option for premenopausal women with low bone mass, regardless of etiologies, although further research on fracture risk reduction is warranted.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Lee S, Hong N, Cho SJ, et al. Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass. Osteoporos Int. 2025. PMID: 39812671. doi:10.1007/s00198-024-07336-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。